The methodology will allow more detailed studies of Treg in MS especially with the highly activated Treg in Population II, which can be further divided into Th1 and Th17-like Treg, and other markers of activated Treg such as CD39, Class II MHC and PD1. This evidence concerns the gene ENTPD1 and myeloid sarcoma.